AI assistant
Phathom Pharmaceuticals, Inc. — Director's Dealing 2025
Apr 16, 2025
32407_dirs_2025-04-16_c385560e-b1dd-4bec-97a8-2a123941b232.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Phathom Pharmaceuticals, Inc. (PHAT)
CIK: 0001783183
Period of Report: 2025-04-16
Reporting Person: Schroeder Theodore R (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-04-16 | Common Stock | A | 21000 | — | Acquired | 21000 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-04-16 | Common Stock (Right to Buy) | $4.23 | A | 35000 | Acquired | 2035-04-15 | Common Stock (35000) | Direct |
Footnotes
F1: Represents restricted stock units ("RSUs") granted on April 16, 2025. One-third (1/3) of the total number of RSUs granted vest on April 16, 2026, and will vest in substantially equal quarterly installments over the twenty-four (24) months thereafter, subject to the Reporting Person's continuous service to the Issuer on the applicable vesting dates. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
F2: The stock option will vest with respect to one-third (1/3) of the shares of common stock on April 16, 2026, and will vest in substantially equal quarterly installments over the twenty-four (24) months thereafter, subject to the Reporting Person's continuous service to the Issuer on the applicable vesting dates.